首页|期刊导航|外科理论与实践|肝细胞癌的转化治疗中几个重要却尚无答案的问题

肝细胞癌的转化治疗中几个重要却尚无答案的问题OACSTPCD

Conversion therapy of hepatocellular carcinoma:some pivotal issues to be resolved

中文摘要英文摘要

靶向药物和免疫检查点抑制剂等系统治疗显著提高了晚期不可切除肝细胞癌病人的预后,但仍难以达到长期生存.转化治疗作为系统治疗与外科治疗结合的主要方向之一,使部分不可切除的肝细胞癌病人获得根治性切除与治愈的机会,近年在国内不同中心广泛开展,并在2021年发布首个《肝癌转化治疗中国专家共识》.同时应看到,在肝癌转化治疗的理论与实践中,还存在诸多关键性问题,目前尚无充足的循证证据回答.积极思考、探索并最终回答这些问题,对于建立、推广肝癌转化治疗的标准化理论体系至关重要.

Progress in the systemic therapies,represented by the molecular target therapies and immune checkpoint inhibitors(ICIs),have significantly improved the prognosis of unresectable hepatocellular carcinoma(uHCC),but long term survial remains limitted.As one of the major combination of systemic and surgical therapies,conversion therapy provides potentially curative opportunity to some uHCC patients.It is widely reported from different domestic centers.The first Chinese expert consensus about it was released in 2021.Yet at the same time,there are many key issues in the practice and theory remains to be resolved.Actively thinking,exploring and finally resolving these issues are essential for establishing and promoting the standardized theoretical system of uHCC conversion therapy.

赵磊;钟敬涛;孙惠川

山东省肿瘤防治研究院(山东省肿瘤医院)肝胆外科,山东第一医科大学(山东省医学科学院),山东 济南 250117山东省肿瘤防治研究院(山东省肿瘤医院)肝胆外科,山东第一医科大学(山东省医学科学院),山东 济南 250117复旦大学附属中山医院肝癌研究所 肝肿瘤外科,上海 200032

临床医学

肝细胞癌转化治疗靶向治疗免疫检查点抑制剂系统性治疗手术切除

Hepatocellular carcinomaConversion therapyTarget therapyImmune checkpoint inhibitor(ICI)Systemic therapySurgical resection

《外科理论与实践》 2024 (2)

106-113,8

山东省重点与研发计划重特大疾病"防诊控治康"科技示范工程(2021SFGC0501)

10.16139/j.1007-9610.2024.02.03

评论